← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Senex Biotechnology, Inc.
Columbia, SC
$6,772,185
Total funding
12
Grants
Funding over time
peak $1.1M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,772,185 · 12
By mechanism
R44$4,518,399 · 3
R43$1,853,786 · 8
R41$400,000 · 1
Investigators at Senex Biotechnology, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
CDK8/19 inhibitors for therapy of advanced prostate cancer$1,130,935
R44 · FY2020 · CA
CDK3-inhibiting anticancer agents$1,064,678
R44 · FY2011 · CA
CDK8/19 inhibitors for therapy of advanced prostate cancer$846,340
R44 · FY2021 · CA
Inhibitors of disease-promoting activities of senescence$611,473
R44 · FY2008 · CA
CDK3-inhibiting anticancer agents$473,945
R44 · FY2012 · CA
Preventing in vivo resistance to PI3K/AKT/mTOR inhibitors through Mediator kinase inhibition$400,000
R43 · FY2022 · CA
Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer$400,000
R41 · FY2025 · CA
CDK8/19 inhibitor for the treatment of HER2+ breast cancer$299,993
R43 · FY2017 · CA
Enhancing cytarabine efficacy in leukemia through CDK8/19 inhibition$299,891
R43 · FY2017 · CA
Targeting CDK8 for the treatment of vein graft failure$299,151
R43 · FY2017 · HL
CDK8/19 inhibitors for therapy of advanced prostate cancer$240,750
R43 · FY2015 · CA
Inhibitors of disease-promoting activities of senescence$200,000
R44 · FY2009 · CA
Inhibitors of disease-promoting activities of senescence$191,028
R44 · FY2009 · CA
Small Molecules Inducing BTG1 Transcription$107,001
R43 · FY2008 · GM
CDK3-inhibiting anticancer agents$107,000
R43 · FY2009 · CA
Inhibitors of disease-promoting activities of senescence$100,000
R43 · FY2006 · AG